Download PDF
Planta Med 2017; 83(01/02): 70-77
DOI: 10.1055/s-0042-108589
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Astagalus Polysaccharide Attenuates Murine Colitis through Inhibiton of the NLRP3 Inflammasome

Zhiqiang Tian   *
1   Institute of Immunology, PLA, Third Military Medical University, Chongqing, China
,
Yao Liu
2   Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing, China
,
Bo Yang
2   Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing, China
,
Ji Zhang
1   Institute of Immunology, PLA, Third Military Medical University, Chongqing, China
,
Haiyang He
1   Institute of Immunology, PLA, Third Military Medical University, Chongqing, China
,
Hui Ge
3   Weifang Municipal Center for Disease Control and Prevention, Weifang, Shandong, China
,
Yuzhang Wu
1   Institute of Immunology, PLA, Third Military Medical University, Chongqing, China
,
Zigang Shen   *
1   Institute of Immunology, PLA, Third Military Medical University, Chongqing, China
› Author Affiliations
Further Information

Publication History

received 25 March 2015
revised 24 April 2016

accepted 28 April 2016

Publication Date:
09 June 2016 (online)

    Permissions and Reprints

Abstract

Astragalus polysaccharide is an important bioactive component of Astragalus membranaceus, an herb used in traditional Chinese medicine for treating inflammatory bowel disease. The NOD-like receptor protein 3 inflammasome plays an important role in the pathogenesis of inflammatory bowel disease. However, little is known about the role of NOD-like receptor protein 3 inflammasome in Astragalus polysaccharide-treated mice with experimental colitis. For this study, we investigated the molecular mechanisms that underlie the treatment of inflammatory bowel disease by Astragalus polysaccharide. We show that Astragalus polysaccharide treatment reduces the disease activity index and histological injury scores compared to the colitis model group. Astragalus polysaccharide also effectively inhibited the expression of NOD-like receptor protein 3, apoptotic speck protein containing a c-terminal caspase recruitment domain, caspase-1, interleukin-18, and interleukin-1β, as shown by quantificational RT-PCR or the enzyme-linked immunosorbent assay. Furthermore, Astragalus polysaccharide treatments produced significant dose-dependent improvements in dextran sulfate sodium-induced experimental colitis. Our data provide the reliable evidence that Astragalus polysaccharide is able to exert a therapeutic effect in dextran sulfate sodium-induced colitis by inhibiting the activation of the NOD-like receptor protein 3 inflammasome, which acts to decrease the production of inflammatory factors such as interleukin-18 and interleukin-1β.

Key words

Astragalus membranaceus - Leguminosae - Astragalus polysaccharide - inflammatory bowel disease - NLRP3 inflammasome

* These authors contributed equally to this manuscript.


Supporting Information

 

  • References

  • 1 Cummings JH, Macfarlane GT, Macfarlane S. Intestinal bacteria and ulcerative colitis. Curr Issues Intest Microbiol 2003; 4: 9-20
    PubMedGoogle Scholar
  • 2 Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney K, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79
    CrossrefPubMedGoogle Scholar
  • 3 Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012; 380: 1606-1619
    CrossrefPubMedGoogle Scholar
  • 4 Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078
    CrossrefPubMedGoogle Scholar
  • 5 Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549
    CrossrefPubMedGoogle Scholar
  • 6 Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999; 169: 195-207
    CrossrefPubMedGoogle Scholar
  • 7 Rhodes JM. Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Lancet 1996; 347: 40-44
    CrossrefPubMedGoogle Scholar
  • 8 Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801
    CrossrefPubMedGoogle Scholar
  • 9 Franchi L, McDonald C, Kanneganti TD, Amer A, Núñez G. Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense. J Immunol 2006; 177: 3507-3513
    CrossrefPubMedGoogle Scholar
  • 10 Kanneganti TD, Lamkanfi M, Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007; 27: 549-559
    CrossrefPubMedGoogle Scholar
  • 11 Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-145
    CrossrefPubMedGoogle Scholar
  • 12 Fukata M, Abreu MT. Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol 2009; 9: 680-687
    CrossrefPubMedGoogle Scholar
  • 13 Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, Roose-Girma M, Erichson S, Dixit VM. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004; 430: 213-218
    CrossrefPubMedGoogle Scholar
  • 14 Yamamoto T, Maruyama Y, Umegae S, Matsumoto K, Saniabadi AR. Mucosal inflammation in the terminal ileum of ulcerative colitis patients: endoscopic findings and cytokine profiles. Dig Liver Dis 2008; 40: 253-259
    CrossrefPubMedGoogle Scholar
  • 15 Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz E, Schnurr M. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59: 1192-1199
    CrossrefPubMedGoogle Scholar
  • 16 Lopetuso LR, Chowdhry S, Pizarro TT. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol 2013; 4: 181
    PubMedGoogle Scholar
  • 17 Reuter BK, Pizarro TT. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?. Eur J Immunol 2004; 34: 2347-2355
    CrossrefPubMedGoogle Scholar
  • 18 Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32: 379-391
    CrossrefPubMedGoogle Scholar
  • 19 Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207: 1045-1056
    CrossrefPubMedGoogle Scholar
  • 20 Bauer C, Duewell P, Lehr HA, Endres S, Schnurr M. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis 2012; 30: S82-S90
    CrossrefPubMedGoogle Scholar
  • 21 Lee SJ, Oh SG, Seo SW, Ahn HJ, Geum D, Cho JJ, Park CS. Oral administration of Astragalus membranaceus inhibits the development of DNFB-induced dermatitis in NC/Nga mice. Biol Pharm Bull 2007; 30: 1468-1471
    CrossrefPubMedGoogle Scholar
  • 22 Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus . Cancer Lett 2007; 252: 43-54
    CrossrefPubMedGoogle Scholar
  • 23 Ma X, Zhang K, Li H, Han S, Ma Z, Tu P. Extracts from Astragalus membranaceus limit myocardial cell death and improve cardiac function in a rat model of myocardial ischemia. J Ethnopharmacol 2013; 149: 720-728
    CrossrefPubMedGoogle Scholar
  • 24 Yang M, Lin HB, Gong S, Chen PY, Geng LL, Zeng YM, Li DY. Effect of Astragalus polysaccharides on expression of TNF-alpha, IL-1beta and NFATc4 in a rat model of experimental colitis. Cytokine 2014; 70: 81-86
    CrossrefPubMedGoogle Scholar
  • 25 Zhao L, Wu H, Zhao A, Lu H, Sun W, Yang Y, Xin X, Zou H, Qiu M, Jia W. The in vivo and in vitro study of polysaccharides from a two-herb formula on ulcerative colitis and potential mechanism of action. J Ethnopharmacol 2014; 153: 151-159
    CrossrefPubMedGoogle Scholar
  • 26 Ward FM, Bodger K, Daly MJ, Heatley RV. Clinical economics review: medical management of inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 15-25
    CrossrefPubMedGoogle Scholar
  • 27 Mileti E, Matteoli G, Iliev ID, Rescigno M. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 2009; 4: e7056
    CrossrefPubMedGoogle Scholar
  • 28 Chen YC, Chen FP, Chen TJ, Chou LF, Hwang SJ. Patterns of traditional Chinese medicine use in patients with inflammatory bowel disease: a population study in Taiwan. Hepatogastroenterology 2008; 55: 467-470
    PubMedGoogle Scholar
  • 29 Salaga M, Zatorski H, Sobczak M, Chen C, Fichna J. Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review. Curr Treat Options Oncol 2014; 15: 405-420
    CrossrefPubMedGoogle Scholar
  • 30 Ling XH, Yu X, Kong DJ, Hu CY, Hong Y, Yang XM. Treatment of inflammatory bowel disease with Chinese drugs administered by both oral intake and retention enema. Chin J Integr Med 2010; 16: 222-228
    CrossrefPubMedGoogle Scholar
  • 31 Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, Baba N, Libioulle C, Belaiche J, Bitton A, Gaudet D, Cohen A, Langelier D, Fortin PR, Wither JE, Sarfati M, Rutgeerts P, Rioux JD, Vermeire S, Hudson TJ, Franchimont D. Common variants in the NLRP3 region contribute to Crohnʼs disease susceptibility. Nat Genet 2009; 41: 71-76
    CrossrefPubMedGoogle Scholar
  • 32 Carneiro LA, Travassos LH, Girardin SE. Nod-like receptors in innate immunity and inflammatory diseases. Ann Med 2007; 39: 581-593
    CrossrefPubMedGoogle Scholar
  • 33 Zaki MH, Lamkanfi M, Kanneganti TD. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol 2011; 32: 171-179
    CrossrefPubMedGoogle Scholar
  • 34 Gao YJ, Zhu F, Qian JM, Dai JY. Therapeutic and immunoregulatory effect of GATA-Binding protein-3/T-Box expressed in T-cells ratio of Astragalus polysaccharides on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats. Chin J Integr Med DOI: 10.1007/s11655-015-2151-0. advance online publication 26 August 2015
    PubMedGoogle Scholar
  • 35 Liu Y, Liu F, Yang Y, Li D, Lv J, Qu Y, Sun F, Chen J, Shi Y, Xia P. Astragalus polysaccharide ameliorates ionizing radiation-induced oxidative stress in mice. Int J Biol Macromol 2014; 68: 209-214
    CrossrefPubMedGoogle Scholar
  • 36 Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546
    CrossrefPubMedGoogle Scholar
  • 37 Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998; 114: 385-391
    CrossrefPubMedGoogle Scholar